The Role of LHRH Antagonists in the Treatment of Prostate Cancer
June 09, 2009
Physicians have known since 1941 that testosterone suppression benefits patients with symptomatic metastatic prostate cancer. The pioneering study in this regard showed that estrogen therapy achieved comparable efficacy to castration by improving acid and alkaline phosphatase levels associated with relief of cancer-related symptoms. More than 6 decades later, however, many of the therapies subsequently developed for achieving androgen deprivation still suffer from serious limitations.